Advertisement

Letters to the Editor

Use of Exenatide for Weight Loss in Patients with Diabetes

Am Fam Physician. 2007 May 1;75(9):1304.

to the editor: The STEPS article on exenatide injection (Byetta) concluded that it is an inconvenient drug with no proven benefits over other drugs for the management of diabetes.1 However, the authors did not discuss the weight loss benefit of exenatide in patients with diabetes who are obese.

In a clinical trial of patients with diabetes who were receiving metformin (Glucophage), the addition of exenatide was associated with progressive weight loss in obese and nonobese patients in a dose-dependent manner compared with placebo.2 When used appropriately as add-on therapy, exenatide has an advantage over sulfonylureas and insulin because it does not increase the risk of hypoglycemia.

As medical director of a bariatric practice, I have seen greater weight loss in obese patients with type 2 diabetes who were receiving exenatide compared with those taking sulfonylureas, thiazolidinediones, or insulin. I also would argue that exenatide is easier to use than insulin because of its prefilled pen design and simple dosing schedule. Medications like exenatide, which may have a positive impact on the “diabesity” epidemic, warrant additional consideration.

Author disclosure: Nothing to disclose.

REFERENCES

1. Ezzo  DC, Ambizas  EM.  Exenatide injection (Byetta): adjunctive therapy for glycemic control.  Am Fam Physician.  2006;73:2213–4.

2. DeFronzo  RA, Ratner  RE, Han  J, Kim  DD, Fineman  MS, Baron  AD.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.  Diabetes Care.  2005;28:1092–100.

editor's note: This letter was sent to the authors of the STEPS article, who declined to reply.

 

Send letters to Kenneth W. Lin, MD, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, telephone number, and fax number. Letters should be fewer than 500 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

Article Tools

Printer-friendly

Share this page

AFP CME Quiz

Get Permissions

Search AFP

 

AFP at a Glance
INDUSTRY INFORMATION
Advertisement
Advertisement